Author of

• 15577

  +

  P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15596

    +

    P3.08-019 - Chemical Ablation Therapy of Recurrent Mediastinal Metastasis (ID 281)

    09:30 - 09:30  |  Author(s): X. Xu
    • Abstract

    Background:
    To evaluate the treatment of post-radiotherapy recurrent mediastinal nodal metastasis.
    
    Methods:
    Post-radiotherapy thoracic cancer patients with mediastinal lymph node recurrence were enrolled in this study. Patients were randomized into the Radiation (+/- Chemotherapy) or the chemoablation group. Patients randomized to the chemoradiotherapy group received additional radiotherapy, second-line chemotherapy, or both. Patients randomized to the chemoablation group received CT-guided percutaneous chemical ablation. Clinical remission was assessed at one month by contrast CT. Reirradiation dose ranged from 2200-3600 cGy depending on dose limiting constraints in consideration of prior radiotherapy dose. The RECIST criteria were used in the evaluation of response to therapy. The median length of follow-up is six months.
    
    Results:
    Thirty-one patients were enrolled in the study. In the chemoradiation group, all patients underwent CT imaging at one month follow-up. Among these patients, 7 had progressive disease (PD), 5 had stable disease (SD), and 4 had partial response (PR). The six-month survival rate was 12.5%. In the chemoablation group at one-month follow-up, 12 patients had SD and 3 patients had PR and the six-month survival rate was 46.6%.
    
    Conclusion:
    Our results suggest that chemoablation therapy as salvage treatment after post-radiotherapy relapse is efficacious and safe.